Drug Profile
Docosahexaenoic acid/eicosapentaenoic acid/ - Sancilio and Company
Alternative Names: Eicosapentaenoic acid/docosahexaenoic acid – Sancilio and Company; SC 401; SC401BLatest Information Update: 14 Oct 2021
Price :
$50
*
At a glance
- Originator Sancilio & Company
- Class Antihyperlipidaemics; Docosahexaenoic acids; Eicosanoids; Omega 3 fatty acids; Unsaturated fatty acids
- Mechanism of Action Lipid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypertriglyceridaemia
Most Recent Events
- 14 Oct 2021 No development reported - Phase-II for Hypertriglyceridaemia in USA (PO)
- 17 Jan 2018 Phase-II development in Hypertriglyceridaemia is ongoing in USA (PO) (Sancilio and Company pipeline, January 2018)
- 01 Mar 2017 Pharmacokinetics data from a phase I trial in Hypertriglyceridaemia released by Sancilio and Company